[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355932-105":59,"doc-detail-355932-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-pan-tumor-landscape-of-gene-amplifications-and-copy-number-amplification-ratio-for-established-and-emerging-clinical-targets","The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets","","Gene copy number (CN) amplifications and protein overexpression function as established and emerging therapeutic targets across multiple tumor types, yet detection and CN quantitation vary by methodology. This study evaluated a pan-tumor cohort using hybrid-capture comprehensive genomic profiling to generate genome-wide CN models estimating purity, ploidy, and segment-level CN. AmpRatio was computed by dividing gene CN by sample ploidy, then linked ERBB2 AmpRatio with HER2 IHC/FISH status and outcomes on anti-HER2 therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-pan-tumor-landscape-of-gene-amplifications-and-copy-number-amplification-ratio-for-established-and-emerging-clinical-targets/355932/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-pan-tumor-landscape-of-gene-amplifications-and-copy-number-amplification-ratio-for-established-and-emerging-clinical-targets/355932.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the study investigate?","Question",{"text":112,"@type":113},"The study investigates the pan-tumor landscape of gene amplifications and introduces AmpRatio, a method for CN quantitation across established and emerging clinical targets.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is AmpRatio calculated in this work?",{"text":117,"@type":113},"AmpRatio is calculated by dividing gene copy number (CN) by sample ploidy for each sample.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the relationship between ERBB2 AmpRatio and HER2 status/outcomes?",{"text":121,"@type":113},"ERBB2 AmpRatio is associated with HER2 positivity determined by IHC/FISH in gastroesophageal and breast cancers, and it stratifies outcomes among patients receiving anti-HER2 therapies within ERBB2-amplified and HER2-defined populations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355932,1790190922,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets  \nJessica K. Lee1, Julia C. F. Quintanilha1, Kuei-Ting Chen1, Bernard Fendler1,  \nCandice Francheska B. Tambaoan1, Ryon Graf1, Nicole Odzer2, Lajos Pusztai2, Maryam Lustberg2, Harshabad Singh3, Matthew Strickland3, Tess A. O’Meara4, Sara M. Tolaney4, Timothy A. Yap5, Jeffrey Ross1,6, Amaya Gasco Hernandez1, Brennan Decker1, Richard S. P. Huang1, Samuel J. Klempner3, Ethan S. Sokol1, and Alexa B. Schrock1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Gene copy number (CN) amplifications and protein overexpression are common drug targets, and detection relies on various methodologies, including next-generation sequencing– based CN, immunohistochemistry (IHC), and in situ hybridization (ISH) . We investigated the pan-tumor landscape of amplifications and developed AmpRatio, a novel method of CN quantitation.\u003Cbr>Experimental Design: Pan-tumor tissue (N ¼ 486,340) and liquid (N ¼ 85,635) samples underwent hybrid capture–based comprehensive genomic profiling. A genome-wide CN model for each sample was generated to estimate the purity, ploidy, and segment-level CN. AmpRatio was calculated by dividing gene CN/sample ploidy. A US-based deidentified clinicogenomic database was utilized to assess the relationship between ERBB2 AmpRatio and HER2 IHC/FISH and outcomes on anti-HER2 therapies.\u003Cbr>Results: Amplifications with varying degrees of gain were reported in 38.6% of pan-tumor tissue samples, most frequently\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | MYC (5.6%), 11q13 (5.2%), ERBB2 (5.2%), and CCNE1 (3.2%) . ERBB2 AmpRatio was associated with HER2 positivity by IHC/ FISH in gastroesophageal [overall percent agreement (OPA) 90%] and breast (OPA 95%) cancers. Among patients treated with anti-HER2 therapies, ERBB2 AmpRatio significantly stratified outcomes within the ERBB2-amplified and IHC-defined HER2+ and HER2-low/ultralow populations. High concordance (sensitivity 88%) of amplification detection in liquid biopsy versus tissue was associated with higher AmpRatio and ctDNA tumor fraction ≥20% .\u003Cbr>Conclusions: CN amplifications are prevalent and diverse biomarkers, and AmpRatio is variable across genes and tumor types. ERBB2 AmpRatio is associated with outcomes to HER2-directed therapies and may have utility alongside IHC for clinical decision-making. With the increasing number of therapies targeting amplifications/overexpression, it will be important to define harmonized methods for CN quantification for optimal patient selection. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nGene copy number (CN) amplifications and protein overexpression represent established and emerging therapeutic targets across tumor types. The monoclonal antibody (mAb) trastuzumab was approved in 1998 for the treatment of metastatic breast cancers ","cbCaicbPreMq4D47","https://ap.wps.com/l/cbCaicbPreMq4D47","pdf",4000279,14,"English","# Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What does the study investigate?\",\"answer\":\"The study investigates the pan-tumor landscape of gene amplifications and introduces AmpRatio, a method for CN quantitation across established and emerging clinical targets.\"},{\"question\":\"How is AmpRatio calculated in this work?\",\"answer\":\"AmpRatio is calculated by dividing gene copy number (CN) by sample ploidy for each sample.\"},{\"question\":\"What is the relationship between ERBB2 AmpRatio and HER2 status/outcomes?\",\"answer\":\"ERBB2 AmpRatio is associated with HER2 positivity determined by IHC/FISH in gastroesophageal and breast cancers, and it stratifies outcomes among patients receiving anti-HER2 therapies within ERBB2-amplified and HER2-defined populations.\"}]","The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets | PDF",1790121810,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2908fbc342ac6711cba0ea08a6d9819.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35e0c831c34b826d00225f0ca560c2c5.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa0247d6c27cd5e763c25bc97ae9723c.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7485d92edee2faa08f30dc5b4f93108.webp",980,1311]